WHWK vs. IMAB, ALT, CTMX, CADL, DSGN, AMRN, ACB, LRMR, OCGN, and GLUE
Should you be buying Whitehawk Therapeutics stock or one of its competitors? The main competitors of Whitehawk Therapeutics include I-Mab (IMAB), Altimmune (ALT), CytomX Therapeutics (CTMX), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Amarin (AMRN), Aurora Cannabis (ACB), Larimar Therapeutics (LRMR), Ocugen (OCGN), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.
Whitehawk Therapeutics vs. Its Competitors
Whitehawk Therapeutics (NASDAQ:WHWK) and I-Mab (NASDAQ:IMAB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.
Whitehawk Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.
52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Whitehawk Therapeutics has a net margin of 99.42% compared to I-Mab's net margin of 0.00%. I-Mab's return on equity of -19.65% beat Whitehawk Therapeutics' return on equity.
I-Mab has lower revenue, but higher earnings than Whitehawk Therapeutics.
I-Mab has a consensus price target of $7.00, suggesting a potential upside of 59.82%. Given I-Mab's stronger consensus rating and higher possible upside, analysts clearly believe I-Mab is more favorable than Whitehawk Therapeutics.
In the previous week, I-Mab had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 3 mentions for I-Mab and 1 mentions for Whitehawk Therapeutics. I-Mab's average media sentiment score of 0.65 beat Whitehawk Therapeutics' score of 0.00 indicating that I-Mab is being referred to more favorably in the news media.
Summary
I-Mab beats Whitehawk Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Whitehawk Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WHWK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Whitehawk Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WHWK) was last updated on 9/6/2025 by MarketBeat.com Staff
